571188-59-5Relevant articles and documents
Copper-catalyzed selective C-N bond formation with 2-amino, 2-hydroxy and 2-bromo-5-halopyridine
Roy, Swarnali,Paul, Barnali,Mukherjee, Ayan,Kundu, Biswajit,Talukdar, Arindam
, p. 44366 - 44370 (2017)
A copper-catalyzed 1,2-diol amination at the electron-rich C-5 position of unprotected 2-amino/2-hydroxy-5-halopyridine provided excellent yields. Selective amination preferably at C-5 in 2-bromo-5-iodopyridine was achieved under the same conditions. The selective, generally mild and economical coupling reaction at C-5 position described herein could be achieved with amines, heterocycles and amides.
Discovery of novel and orally bioavailable CDK 4/6 inhibitors with high kinome selectivity, low toxicity and long-acting stability for the treatment of multiple myeloma
Yuan, Kai,Kuang, Wenbin,Chen, Weijiao,Ji, Minghui,Min, Wenjian,Zhu, Yasheng,Hou, Yi,Wang, Xiao,Li, Jiaxing,Wang, Liping,Yang, Peng
, (2021/12/09)
Multiple myeloma (MM) ranks second in malignant hematopoietic cancers, and the most common anti-MM drugs easily generate resistance. CDK4/6 have been validated to play determinant roles in MM, but no remarkable progress has been obtained from clinical trials of CDK4/6 inhibitors for MM. To discover novel CDK6 inhibitors with better potency and high druggability, structure-based virtual screening was conducted to identify compound 10. Further chemical optimization afforded a better derivative, compound 32, which exhibited strong inhibition of CDK4/6 and showed high selectivity over 360+ kinases, including homologous CDKs. The in vivo evaluation demonstrated that compound 32 possessed low toxicity (LD50 > 10,000 mg/kg), favorable bioavailability (F% = 51%), high metabolic stability (t1/2 > 24 h) and strong anti-MM potency. In summary, we discovered a novel CDK4/6 inhibitor bearing favorable drug-like properties and offered a great candidate for MM preclinical studies.
Intermediate compound as well as preparation method and application thereof
-
, (2021/07/24)
The invention discloses an intermediate compound as well as a preparation method and application thereof. The synthesized intermediate compound is used for preparing targeted anti-cancer drugs, such as CDK4, CDK6, DYRK2 and other inhibitors, and is used for preventing and/or treating cancers or tumor related diseases including breast cancer, prostate cancer, lung cancer, multiple myeloma, leukemia, gastric cancer, ovarian cancer, colon cancer, liver cancer, pancreatic cancer and human glioma. The intermediate compound is simple in preparation condition, high in reaction yield and stable in performance.
Method for preparing 4 - (6 -aminopyridine -3 -yl) piperazine -1 - carboxylic acid tert-butyl ester
-
Paragraph 0042; 0050-0054; 0062-0066; 0073-0076, (2021/09/26)
The invention discloses a method for preparing 4 - (6 - aminopyrid -3 -yl) piperazine -1 - carboxylic acid tert-butyl ester, which comprises the following steps of: reacting 2 - aminopyridine with iodine to generate 2 - amino -5 -iodopyridine. Step II: 2 - amino -5 -iodopyridine was subjected to a coupling reaction to obtain 4 - (6 - aminopyrid -3 -yl) piperazine -1 -carboxylic acid tert-butyl ester. The method has the advantages of short synthetic route, high target product yield and low cost.